Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 121 Cr.
- Current Price ₹ 99.7
- High / Low ₹ 262 / 95.7
- Stock P/E 6.33
- Book Value ₹ 100
- Dividend Yield 0.00 %
- ROCE 61.5 %
- ROE 59.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.00 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 63.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Other Food Products
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 87 | 131 | 132 | 203 | 193 | |
| 80 | 120 | 111 | 171 | 167 | |
| Operating Profit | 7 | 11 | 21 | 33 | 27 |
| OPM % | 8% | 8% | 16% | 16% | 14% |
| 0 | 0 | 1 | 2 | 1 | |
| Interest | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | 7 | 11 | 20 | 33 | 26 |
| Tax % | 25% | 27% | 27% | 26% | |
| 5 | 8 | 15 | 24 | 19 | |
| EPS in Rs | 40.38 | 56.45 | 107.00 | 25.55 | 17.76 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 64% |
| TTM: | 67% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| Last Year: | 59% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 | 12 |
| Reserves | 5 | 13 | 28 | 44 | 109 |
| 6 | 11 | 13 | 17 | 1 | |
| 12 | 12 | 12 | 16 | 15 | |
| Total Liabilities | 25 | 37 | 54 | 86 | 137 |
| 1 | 6 | 5 | 9 | 9 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 24 | 32 | 48 | 77 | 128 | |
| Total Assets | 25 | 37 | 54 | 86 | 137 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -6 | 0 | -0 | 4 | |
| -1 | -5 | -0 | -4 | |
| 7 | 5 | 0 | 3 | |
| Net Cash Flow | -0 | 0 | -0 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 80 | 62 | 87 | 82 |
| Inventory Days | 9 | 25 | 27 | 50 |
| Days Payable | 41 | 34 | 33 | 23 |
| Cash Conversion Cycle | 49 | 53 | 81 | 109 |
| Working Capital Days | 28 | 25 | 66 | 75 |
| ROCE % | 58% | 63% | 62% |
Insights
In beta| Mar 2024 | Sep 2025 | |
|---|---|---|
| Blending Capacity MT/Day ・Standalone data |
|
|
| Domestic Revenue Share % ・Standalone data |
||
| Employee Strength Number ・Standalone data |
||
| Export Revenue Share % ・Standalone data |
||
| Grinding Capacity MT/Day ・Standalone data |
||
| Number of Ingredients Number ・Standalone data |
||
| Number of Trusted Clients Number ・Standalone data |
||
| Warehouse Space Sq. Ft. ・Standalone data |
||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
18 Feb - Invested Rs1.50 Crore via 1,500,000 shares at Rs10 each in Easy Raw Materials on 18 Feb 2026.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 13 Feb
-
Disclosure As Per Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015
12 Feb - Director Shailesh Mehta acquired 52,200 shares (0.58%); disclosed under SEBI PIT Reg 7(2) on 12-Feb-2026.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
11 Feb - Monitoring report: Rs80.08 crore IPO proceeds utilization for quarter ended Dec 31, 2025; no deviations.
-
Appointment of Company Secretary and Compliance Officer
3 Feb - Corrigendum: Company Secretary/Compliance Officer surname corrected to Shreya Dalmia; appointment effective 20 January 2026.
Annual reports
No data available.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.